|
1
|
Czekay RP, Wilkins-Port CE, Higgins SP,
Freytag J, Overstreet JM, Klein RM, Higgins CE, Samarakoon R and
Higgins PJ: PAI-1: An integrator of cell signaling and migration.
Int J Cell Biol. 2011:5624812011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jankun J: Plasminogen activator
inhibitor-1 in kidney pathology (Review). Int J Mol Med.
31:503–510. 2013.PubMed/NCBI
|
|
3
|
Klinger KW, Winqvist R, Riccio A,
Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P,
Watkins P, Douglas R, et al: Plasminogen activator inhibitor type 1
gene is located at region q21.3-q22 of chromosome 7 and genetically
linked with cysticfibrosis. Proc Natl Acad Sci USA. 84:8548–8552.
1987. View Article : Google Scholar
|
|
4
|
Krause MP, Moradi J, Nissar AA, Riddell MC
and Hawke TJ: Inhibition of plasminogen activator inhibitor-1
restores skeletal muscle regeneration in untreated type 1 diabetic
mice. Diabetes. 60:1964–1972. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ricart JM, Ramón LA, Vayá A, España F,
Santaolaria ML, Todolí J, Castelló R, Fontcuberta J and Estellés A:
Fibrinolytic inhibitor levels and polymorphisms in Behcet disease
and their association with thrombosis. Br J Haematol. 141:716–719.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bajou K, Noël A, Gerard RD, Masson V,
Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen
D, et al: Absence of host plasminogen activator inhibitor 1
prevents cancer invasion and vascularization. Nat Med. 4:923–928.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fabre-Guillevin E, Malo M, Cartier-Michaud
A, Peinado H, Moreno-Bueno G, Vallée B, Lawrence DA, Palacios J,
Cano A, Barlovatz-Meimon G, et al: PAI-1 and functional blockade of
SNAI1 in breast cancer cell migration. Breast Cancer Res.
10:R1002008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smit JW, van der Pluijm G, Romijn HA,
Löwik CW, Morreau H and Goslings BM: Degradation of extracellular
matrix by metastatic follicular thyroid carcinoma cell lines: role
of the plasmin activation system. Thyroid. 9:913–919. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maillard C, Jost M, Rømer MU, Brunner N,
Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, et al:
Host plasminogen activator inhibitor-1 promotes human skin
carcinoma progression in a stage-dependent manner. Neoplasia.
7:57–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Riddick AC, Shukla CJ, Pennington CJ, Bass
R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland
NJ, et al: Identification of degradome components associated with
prostate cancer progression by expression analysis of human
prostatic tissues. Br J Cancer. 92:2171–2180. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vial D and McKeown-Longo PJ: PAI1
stimulates assembly of the fibronectin matrix in osteosarcoma cells
through crosstalk between the alphavbeta5 and alpha5beta1
integrins. J Cell Sci. 121:1661–1670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Woo M, Park K, Nam J and Kim JC: Clinical
implications of matrix metalloproteinase-1, -3, -7, -9, -12, and
plasminogen activator inhibitor-1 gene polymorphisms in colorectal
cancer. J Gastroenterol Hepatol. 22:1064–1070. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanekom GS, Stubbings HM and Kidson SH:
The active fraction of plasmatic plasminogen activator inhibitor
type 1 as a possible indicator of increased risk for metastatic
melanoma. Cancer Detect Prev. 26:50–59. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lara PC, Lloret M, Valenciano A, Clavo B,
Pinar B, Rey A and Henríquez-Hernández LA: Plasminogen activator
inhibitor-1 (PAI-1) expression in relation to hypoxia and
oncoproteins in clinical cervical tumors. Strahlenther Onkol.
188:1139–1145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malinowsky K, Wolff C, Berg D, Schuster T,
Walch A, Bronger H, Mannsperger H, Schmidt C, Korf U, Höfler H, et
al: uPA and PAI-1-related signaling pathways differ between primary
breast cancers and lymph node metastases. Transl Oncol. 5:98–104.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sternlicht MD, Dunning AM, Moore DH,
Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldman FM, Ponder BA
and Werb Z: Prognostic value of PAI1 in invasive breast cancer:
evidence that tumor-specific factors are more important than
genetic variation in regulating PAI1 expression. Cancer Epidemiol
Biomarkers Prev. 15:2107–2114. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meacham CE and Morrison SJ: Tumour
heterogeneity and cancer cell plasticity. Nature. 501:328–337.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen X, Rycaj K, Liu X and Tang DG: New
insights into prostate cancer stem cells. Cell Cycle. 12:579–586.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dick JE: Stem cell concepts renew cancer
research. Blood. 112:4793–4807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
López J, Valdez-Morales FJ,
Benítez-Bribiesca L, Cerbón M and Carrancá AG: Normal and cancer
stem cells of the human female reproductive system. Reprod Biol
Endocrinol. 11:532013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Skibinski A and Kuperwasser C: The origin
of breast tumor heterogeneity. Oncogene. 34:5309–5316. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Triscott J, Rose Pambid M and Dunn SE:
Concise review: bullseye: targeting cancer stem cells to improve
the treatment of gliomas by repurposing disulfiram. Stem Cells.
33:1042–1046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zeki SS, Graham TA and Wright NA: Stem
cells and their implications for colorectal cancer. Nat Rev
Gastroenterol Hepatol. 8:90–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hirata N, Yamada S, Shoda T, Kurihara M,
Sekino Y and Kanda Y: Sphingosine-1-phosphate promotes expansion of
cancer stem cells via S1PR3 by a ligand-independent Notch
activation. Nat Commun. 5:48062014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alonso-Alconada L, Muinelo-Romay L,
Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, Wik E, Hapangama D,
Coenegrachts L, Cano A, et al: Molecular profiling of circulating
tumor cells links plasticity to the metastatic process in
endometrial cancer. Mol Cancer. 13:2232014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma I and Allan AL: The role of human
aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell
Rev. 7:292–306. 2011. View Article : Google Scholar
|
|
28
|
Penumatsa K, Edassery SL, Barua A,
Bradaric MJ and Luborsky JL: Differential expression of aldehyde
dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian
tumors. J Ovarian Res. 3:282010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pisanu ME, Noto A, De Vitis C, Masiello
MG, Coluccia P, Proietti S, Giovagnoli MR, Ricci A, Giarnieri E,
Cucina A, et al: Lung cancer stem cell lose their stemness default
state after exposure to microgravity. Biomed Res Int.
2014:4702532014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pors K and Moreb JS: Aldehyde
dehydrogenases in cancer: An opportunity for biomarker and drug
development? Drug Discov Today. 19:1953–1963. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raha D, Wilson TR, Peng J, Peterson D, Yue
P, Evangelista M, Wilson C, Merchant M and Settleman J: The cancer
stem cell marker aldehyde dehydrogenase is required to maintain a
drug-tolerant tumor cell subpopulation. Cancer Res. 74:3579–3590.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Warrier S, Bhuvanalakshmi G, Arfuso F,
Rajan G, Millward M and Dharmarajan A: Cancer stem-like cells from
head and neck cancers are chemosensitized by the Wnt antagonist,
sFRP4, by inducing apoptosis, decreasing stemness, drug resistance
and epithelial to mesenchymal transition. Cancer Gene Ther.
21:381–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Watanabe Y, Yoshimura K, Yoshikawa K,
Tsunedomi R, Shindo Y, Matsukuma S, Maeda N, Kanekiyo S, Suzuki N,
Kuramasu A, et al: A stem cell medium containing neural stimulating
factor induces a pancreatic cancer stem-like cell-enriched
population. Int J Oncol. 45:1857–1866. 2014.PubMed/NCBI
|
|
34
|
Liu SY and Zheng PS: High aldehyde
dehydrogenase activity identifies cancer stem cells in human
cervical cancer. Oncotarget. 4:2462–2475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Isogai C, Laug WE, Shimada H, Declerck PJ,
Stins MF, Durden DL, Erdreich-Epstein A and DeClerck YA:
Plasminogen activator inhibitor-1 promotes angiogenesis by
stimulating endothelial cell migration toward fibronectin. Cancer
Res. 61:5587–5594. 2001.PubMed/NCBI
|
|
36
|
Taguchi A, Kawana K, Tomio K, Yamashita A,
Isobe Y, Nagasaka K, Koga K, Inoue T, Nishida H, Kojima S, et al:
Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts
(CAFs) is suppressed by omega-3 polyunsaturated fatty acids in
vitro and in vivo. PLoS One. 9:e896052014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goldberg I, Davidson B, Lerner-Geva L,
Gotlieb WH, Ben-Baruch G, Novikov I and Kopolovic J: Expression of
extracellular matrix proteins in cervical squamous cell carcinoma -
a clinicopathological study. J Clin Pathol. 51:781–785. 1998.
View Article : Google Scholar
|
|
38
|
Han B, Nakamura M, Zhou G, Ishii A,
Nakamura A, Bai Y, Mori I and Kakudo K: Calcitonin inhibits
invasion of breast cancer cells: Involvement of urokinase-type
plasminogen activator (uPA) and uPA receptor. Int J Oncol.
28:807–814. 2006.PubMed/NCBI
|
|
39
|
Hildenbrand R and Schaaf A: The
urokinase-system in tumor tissue stroma of the breast and breast
cancer cell invasion. Int J Oncol. 34:15–23. 2009.
|
|
40
|
Roomi MW, Kalinovsky T, Niedzwiecki A and
Rath M: Modulation of uPA, MMPs and their inhibitors by a novel
nutrient mixture in human glioblastoma cell lines. Int J Oncol.
45:887–894. 2014.PubMed/NCBI
|
|
41
|
Chung CL, Sheu JR, Liu HE, Chang SC, Chou
YC, Chen WL, Chou DS and Hsiao G: Dynasore, a dynamin inhibitor,
induces PAI-1 expression in MeT-5A human pleural mesothelial cells.
Am J Respir Cell Mol Biol. 40:692–700. 2009. View Article : Google Scholar
|
|
42
|
Baramova EN, Bajou K, Remacle A, L'Hoir C,
Krell HW, Weidle UH, Noel A and Foidart JM: Involvement of
PA/plasmin system in the processing of pro-MMP-9 and in the second
step of pro-MMP-2 activation. FEBS Lett. 405:157–162. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Izuhara Y, Yamaoka N, Kodama H, Dan T,
Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C and
Miyata T: A novel inhibitor of plasminogen activator inhibitor-1
provides antithrombotic benefits devoid of bleeding effect in
nonhuman primates. J Cereb Blood Flow Metab. 30:904–912. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Marchina E and Barlati S: Degradation of
human plasma and extracellular matrix fibronectin by tissue type
plasminogen activator and urokinase. Int J Biochem Cell Biol.
28:1141–1150. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ota H, Akishita M, Eto M, Iijima K, Kaneki
M and Ouchi Y: Sirt1 modulates premature senescence-like phenotype
in human endothelial cells. J Mol Cell Cardiol. 43:571–579. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Calvanese V, Lara E, Suárez-Alvarez B, Abu
Dawud R, Vázquez-Chantada M, Martínez-Chantar ML, Embade N,
López-Nieva P, Horrillo A, Hmadcha A, et al: Sirtuin 1 regulation
of developmental genes during differentiation of stem cells. Proc
Natl Acad Sci USA. 107:13736–13741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wan YZ, Gao P, Zhou S, Zhang ZQ, Hao DL,
Lian LS, Li YJ, Chen HZ and Liu DP: SIRT1-mediated epigenetic
downregulation of plasminogen activator inhibitor-1 prevents
vascular endothelial replicative senescence. Aging Cell.
13:890–899. 2014. View Article : Google Scholar : PubMed/NCBI
|
